Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $4.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Actinium Pharmaceuticals’ promising developments and financial health. The company is set to release multiple data readouts in the first half of 2026, particularly focusing on Actimab-A, which could potentially enhance its market position. Additionally, the ATNM-400 program is gaining strategic importance with its strengthening preclinical data package, showing promise in prostate and lung cancers, and upcoming breast cancer data could further expand its opportunities.
Financially, Actinium reported better-than-expected earnings for the third quarter of 2025, with a narrower loss per share than anticipated. The company also has a solid financial footing, ending the quarter with $53.4 million, which is expected to support operations for at least the next year. Furthermore, Actinium’s alignment with the FDA for a pivotal Phase 2/3 trial and the exploration of Actimab-A in combination with other therapies underscore its potential for future growth and success.
According to TipRanks, Pantginis is a 4-star analyst with an average return of 5.4% and a 44.11% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Celldex, and Esperion.
In another report released on November 4, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target.